| scholarly article | Q13442814 |
| P50 | author | Somdet Srichairatanakool | Q56806566 |
| P2093 | author name string | Suthat Fucharoen | |
| Noppadol Siritanaratkul | |||
| Narumol Panichkul | |||
| Ratiya Charoensakdi | |||
| Ruchaneekorn W Kalpravidh | |||
| Suneerat Hatairaktham | |||
| Orn-uma Yanpanitch | |||
| P2860 | cites work | Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 |
| Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator | Q24652363 | ||
| Exposure of platelet membrane phosphatidylserine regulates blood coagulation | Q28180138 | ||
| Beta-thalassemia | Q28272228 | ||
| Thrombotic thrombocytopenic purpura: reducing the risk? | Q33393828 | ||
| Regulation of redox glutathione levels and gene transcription in lung inflammation: therapeutic approaches. | Q33989877 | ||
| The importance of non-transferrin bound iron in disorders of iron metabolism | Q34094818 | ||
| Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. | Q34205528 | ||
| Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis | Q34476161 | ||
| Antioxidant nutrients and mycotoxins | Q34904411 | ||
| The role of labile iron pool in cardiovascular diseases | Q35818006 | ||
| Nrf2 as a novel molecular target for chemoprevention | Q36137929 | ||
| Treating thalassemia major-related iron overload: the role of deferiprone | Q36344669 | ||
| The Benefits of vitamin E on liver function and the hemopoietic System in thalassemia Patients | Q37560067 | ||
| Non-transferrin bound iron: a key role in iron overload and iron toxicity | Q37920197 | ||
| Iron overload in β-thalassemia intermedia: an emerging concern. | Q38083182 | ||
| Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. | Q38986553 | ||
| Detection of PF3 availability in whole blood from volunteers and beta-thalassemia/HbE patients: a promising method for prediction of thrombotic tendency | Q41080863 | ||
| Pathophysiologic implications of membrane phospholipid asymmetry in blood cells | Q41348596 | ||
| Vitamin E supplementation reduces oxidative stress in beta thalassaemia intermedia. | Q42449492 | ||
| Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator | Q42461969 | ||
| Oral supplements of vitamin E improve measures of oxidative stress in plasma and reduce oxidative damage to LDL and erythrocytes in beta-thalassemia intermedia patients | Q42505009 | ||
| Improvement in oxidative stress and antioxidant parameters in beta-thalassemia/Hb E patients treated with curcuminoids | Q43245550 | ||
| Antioxidant defense status of red blood cells of patients with beta-thalassemia and Ebeta-thalassemia | Q43542984 | ||
| Immunosuppressive therapy regimen and platelet activation in renal transplant patients | Q44184230 | ||
| Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand | Q44503973 | ||
| Effect of sulfur amino acids on stimulus-induced superoxide generation and translocation of p47phox and p67phox to cell membrane in human neutrophils and the scavenging of free radical | Q45255621 | ||
| Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial. | Q46005571 | ||
| Effect of antioxidant therapy on hepatic fibrosis and liver iron concentrations in β-thalassemia major patients. | Q46364415 | ||
| N-acetylcysteine amide (AD4) attenuates oxidative stress in beta-thalassemia blood cells | Q46848491 | ||
| Activated platelet-derived microparticles in thalassaemia. | Q50706406 | ||
| Red blood cell vesicles in thalassemia. | Q50798242 | ||
| Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand. | Q53995645 | ||
| Glutathione redox system in β -thalassemia/Hb E patients. | Q54613909 | ||
| Iron chelation in the biological activity of curcumin. | Q55041704 | ||
| How much vitamin E? ... Just enough! | Q55042686 | ||
| Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine | Q56879285 | ||
| The estimation of red cell superoxide dismutase activity | Q67506981 | ||
| A direct method for quantification of non-transferrin-bound iron | Q68838629 | ||
| The Autoxidation of Human Red Cell Lipids Induced by Hydrogen Peroxide | Q71749140 | ||
| Vitamin E, a modifier of platelet function: rationale and use in cardiovascular and cerebrovascular disease | Q73214306 | ||
| Safety profile of the oral iron chelator deferiprone: a multicentre study | Q73486045 | ||
| In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with beta-thalassaemia major | Q73535703 | ||
| Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca2+ signaling | Q78251657 | ||
| SYNTHESIS OF DIACETYLDICHLOROFLUORESCIN: A STABLE REAGENT FOR FLUOROMETRIC ANALYSIS | Q78493010 | ||
| Effect of coenzyme Q10 as an antioxidant in beta-thalassemia/Hb E patients | Q80013105 | ||
| Vitamin E inhibition on platelet procoagulant activity: involvement of aminophospholipid translocase activity | Q83375709 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 537954 | |
| P577 | publication date | 2015-05-19 | |
| P1433 | published in | Oxidative medicine and cellular longevity | Q26840015 |
| P1476 | title | Treatment of β-Thalassemia/Hemoglobin E with Antioxidant Cocktails Results in Decreased Oxidative Stress, Increased Hemoglobin Concentration, and Improvement of the Hypercoagulable State | |
| P478 | volume | 2015 |
| Q33761211 | European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS). |
| Q36138738 | HbE/β-Thalassemia and Oxidative Stress: The Key to Pathophysiological Mechanisms and Novel Therapeutics |
| Q46460675 | Ischemia-modified albumin as a marker of vascular dysfunction and subclinical atherosclerosis in β-thalassemia major. |
Search more.